BLU - Dosing underway in mid-stage study of BELLUS Health's BLU-5937 in chronic cough

BELLUS Health (BLU) has dosed the first patient in Phase 2b SOOTHE trial evaluating BLU-5937, a P2X3 antagonist, in patients with refractory chronic cough.The 300-subject trial will evaluate three doses of BLU-5937 (12.5 mg, 50 mg and 200 mg BID). The primary efficacy endpoint will be the placebo-adjusted change in the 24-hour cough frequency from baseline to day 28 collected with a cough recorder.An interim analysis is expected to be conducted once 50% of patients have completed the main study and is anticipated in mid-2021. Topline results are expected in Q4 of 2021.Shares are up 1% in premarket

For further details see:

Dosing underway in mid-stage study of BELLUS Health's BLU-5937 in chronic cough